The Anglo-Swedish pharmaceutical giant AstraZeneca faces mounting pressure from shareholders regarding ongoing investigations in China, one of its key markets. The concerns emerged after the detention ...
AstraZeneca’s planned vaccine hub for Liverpool is off the table - business editor Karl Matchett and Whitehall editor Kate ...
In a report released today, Emmanuel Papadakis from Deutsche Bank maintained a Hold rating on AstraZeneca (AZN – Research Report), with a ...
The Netherlands is shaping Europe's future with AI, sustainability and ethical innovation, attracting $2.5bn in global ...
Strong results from AstraZeneca helped London's blue-chip index notch a record close on Thursday, while a dovish majority ...
The boss of AstraZeneca Plc said he does not believe the UK is the worst place to invest, striking a conciliatory tone just ...
Despite the discontinuations, CEO Pascal Soriot said AstraZeneca’s December 2020 acquisition of Alexion was a “fantastic” ...
Hosted on MSN11d
Today-History-Feb15Today in History for Feb. 15: ...
Hector expects AstraZeneca (NASDAQ:AZN) to guide towards a high-single-digit revenue growth for 2025, which would factor in the anticipated effects of Farxiga generics in China. The specifics of this ...
(RTTNews) - The U.S. Food and Drug Administration has approved AstraZeneca Plc. (AZN.L, AZN) and Daiichi Sankyo's (DSKYF.PK) ENHERTU (fam-trastuzumab deruxtecan-nxki) for the treatment of adult ...
The study was partially funded by AstraZeneca, the manufacturer of dapagliflozin.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback